Patent classifications
C12N2760/18841
SOMATIC CELL PRODUCTION SYSTEM
A somatic cell production system comprising a preintroduction cell solution-feeding channel 20 through which a preintroduction cell-containing solution passes, a factor introducing device 30 that is connected to the preintroduction cell solution-feeding channel 20 and introduces a somatic cell inducing factor into preintroduction cells to prepare inducing factor-introduced cells, and a cell preparation device 40 in which the inducing factor-introduced cells are cultured to prepare somatic cells.
METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS
The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.
CYTOTOXIC T CELLS DERIVED FROM HUMAN T CELL-DERIVED IPS CELLS
Cytotoxic T cells derived from human T cell-derived iPS cells may avoid an NK cell missing-self response and may be used for allogeneic administration while maintaining a strong antitumor effect of antigen-specific CTLs. A method may produce a cytotoxic T cell derived from a human T cell-derived iPS cell expressing HLA class I of HLA-restricted class I of an antigen epitope of a CTL and HLA-E. Such a method may include: knocking out all HLA class I of the human T cell-derived iPS cell; introducing a gene of the HLA-restricted HLA class I of the antigen epitope of the CTL and a gene of the HLA-E into the T-iPS cell in which all HLA class I have been knocked out; and redifferentiating the genetically introduced T-iPS cell into a CD8 single-positive T cell.
CELL CULTURE VESSEL AND METHOD FOR CULTURING CELL
A cell culture vessel comprising a housing in which a culture chamber is provided. In the housing, at least two holes that connect the outside of the housing and a culture chamber are provided.
METHOD FOR PRODUCING CARDIOMYOCYTE
A method for producing a cardiomyocyte including preparing a stem cell, introducing a Sendai virus into the stem cell by infection, expressing mRNA for synthesizing an inducing factor from the Sendai viruses in the stem cell to induce a cardiomyocyte from the stem cell.
METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS
The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.
Methods of using ZSCAN4 for rejuvenating human cells
The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.
PRODUCTION METHOD FOR ARTIFICIAL PLURIPOTENT STEM CELLS
The present disclosure provides a production method for artificial pluripotent stem cells, the method comprising preparing somatic cells, and introducing a Sendai virus including reprogramming factor RNA into the somatic cell. The present disclosure also provides a production method for artificial pluripotent stem cells, the method comprising preparing somatic cells, introducing reprogramming factor RNA into the somatic cells using an RNA transfection reagent, and reprogramming the somatic cells in a gel culture medium.
SELECTIVE CD8-POSITIVE T CELL-INDUCING VACCINE ANTIGEN
The present invention provides polypeptides for selectively inducing target antigen-specific CD8-positive T-cell responses. Since induction of human immunodeficiency virus (HIV)-specific CD4-positive T-cell responses by vaccine could promote HIV infection, an HIV vaccine antigen that selectively induces HIV-specific CD8-positive T-cell responses would be useful if obtained. Thus, in the present invention, polypeptide antigens were designed in which 8- to 12-residue amino acid sequences divided from the amino acid sequence of a target antigen protein were connected in an order different from that of the original amino acid sequence. DNA and viral vector vaccines expressing these antigens were tested by inoculation into monkeys. As a result, they were shown to be able to efficiently induce antigen-specific CD8-positive T-cell responses in a selective manner. The instant antigens may be useful as vaccine antigens that induce CD8-positive T cells in a highly selective manner.
Methods of using ZSCAN4 for rejuvenating human cells
The present disclosure relates to methods for increasing telomere length in one or more human adult cells and/or increasing genome stability of one or more human adult cells, for example by contacting one or more human adult cells with an agent that increases expression of Zscan4 in the one or more human adult cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a telomere abnormality, of rejuvenating one or more human adult cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human adult cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 is also provided.